ÂÜÀòÂÒÂ×

Prior to joining Orchestra BioMed in August 2018, Mr. Belsky was Chief Technology Officer for NewPace Ltd., a cardiac rhythm management company based in Israel that is developing an implantable subcutaneous string defibrillator device for patients with atrial fibrillation.

Prior to NewPace, Mr. Belsky was a serial entrepreneur helping to found, and serving as CEO for, a number of start-ups medical innovation companies in Israel, including Novogate Medical Ltd. (2010-2013), a company focused on the development of a novel means of enabling thoraco-apical access for beating heart procedures; Juvenis (2009-2010), a biomaterials company focused on aesthetic and reconstructive surgical procedures; SphinxTech Ltd. (2008-2009), a research and development company focused on medical devices for the treatment of fecal incontinence; and E-Pill Pharma Ltd. (COO, 2003-2007; CEO, 2007-2008), a company developing an oral drug delivery platform to administer peptides and large molecules (such as insulin and growth hormones), small molecules, as well as low bioavailability drugs. Previously, Mr. Belsky was Director, Business Development from 2000 to 2003 for Wavion Ltd., an Israeli company that manufactures and develops carrier-grade WiFi solutions. From 1998 to 2000, Mr. Belsky was Product Manager for Impulse Dynamics Ltd., a medical device company developing an implantable cardiac stimulator for the treatment of heart failure that was co-founded by Yuval Mika, Ph.D., General Manager, and CTO, Cardiac Neuromodulation. Mr. Belsky received his MBA from Heriot-Watt University, his MSc in electrical engineering from Tel Aviv University, and his BSc in physics and mathematics from Hebrew University in Jerusalem.